Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12104/41409
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVazquez-del Mercado, M.
dc.contributor.authorDelgado-Rizo, V.
dc.contributor.authorMunoz-Valle, J.F.
dc.contributor.authorOrozco-Alcala, J.
dc.contributor.authorVolk, H.-D.
dc.contributor.authorArmendariz-Borunda, J.
dc.date.accessioned2015-09-15T17:56:44Z-
dc.date.available2015-09-15T17:56:44Z-
dc.date.issued1999
dc.identifier.urihttp://www.scopus.com/inward/record.url?eid=2-s2.0-0032858456&partnerID=40&md5=1ec8f38042f2881f339ce525dd68e542
dc.identifier.urihttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10544841
dc.identifier.urihttp://hdl.handle.net/20.500.12104/41409-
dc.description.abstractObjective: To determine IL-1?, TNF?, IL-6, IL-4, IL-10, MMP-1, MMP-3 and MMP-13 expression by freshly isolated peripheral blood (PBMC) and synovial fluid mononuclear cells (SFMC) in early, never-treated (ENT-RA) and non-acute, treated rheumatoid arthritis (NAT-RA) patients. To elucidate whether excessive or inadequate interleukin (IL) and metalloprotease (MMP) expression is influenced by the disease duration. Methods: Fourteen RA patients, 7 with early RA (< 1 year of evolution) never treated with corticosteroids or disease-modifying antirheumatic drugs, and 7 patients with non-acute RA (> 2 years of evolution) treated with disease-modifying antirheumatic drugs, were studied by ELISA and quantitative and semiquantitative RT-PCR. A group of 14 healthy subjects matched for sex and age was included. Results: No statistically significant difference in the protein or transcript levels for the cytokines of interest was found between the ENT-RA and NAT-RA groups. The cytokine mRNA expression by freshly isolated PBMC and SFMC in both groups was as follows: IL-1? > TNF? > IL-10 > IL-6, with no mRNA IL-4 expression. In contrast, cytokine serum levels in ENT-RA and NAT-RA patients were detected in inverse order as follows: IL-6 > IL-10, while IL-1?, TNF? and IL-4 were undetectable. MMP-3 mRNA expression by the PBMC of NAT-RA patients was statistically different to that in ENT-RA patients. Similar levels of mRNA expression of MMP-1, MMP-3 and MMP-13 by the PBMC and SFMC in both RA groups were observed. Conclusions A close equilibrium between MMP and pro/anti-inflammatory cytokine production is observed in ENT-RA and NAT-RA patients. This balance is apparently not influenced by the length of the disease. Highly sensitive methods such as quantitative RT-PCR and ELISA, and even studying freshly isolated MC, showed sustained cytokine secretion at the local level (synovial fluid/SFMC) and scarce translation at the peripheral level (serum/PBMC). Expression of MMP mRNA needs to be further evaluated in order to know whether their peripheral expression reflects their local activity in RA patients.
dc.relation.isreferencedbyScopus
dc.relation.isreferencedbyMEDLINE
dc.relation.isreferencedbyWOS
dc.titleExpression of interleukin-1?, tumor necrosis factor ?, interleukins-6, -10 and -4, and metalloproteases by freshly isolated mononuclear cells from early never-treated and non-acute treated rheumatoid arthritis patients
dc.typeArticle
dc.relation.ispartofjournalClinical and Experimental Rheumatology
dc.relation.ispartofvolume17
dc.relation.ispartofissue5
dc.relation.ispartofpage575
dc.relation.ispartofpage583
dc.subject.keywordCytokines; Mononuclear cells; Quantitative RT-PCR; Rheumatoid arthritis; Synovial fluid
dc.contributor.affiliationV�zquez-del Mercado, M., Inst. de Biol. Molecular en Medicina, CUCS, Universidad de Guadalajara, Mexico; Delgado-Rizo, V., Inst. de Biol. Molecular en Medicina, CUCS, Universidad de Guadalajara, Mexico; Mu�oz-Valle, J.F., Inst. de Biol. Molecular en Medicina, CUCS, Universidad de Guadalajara, Mexico; Orozco-Alcal�, J., Hospital Civil de Bel�n, Mexico; Volk, H.-D., Institute for Medical Immunology, University of Berlin, Germany; Armend�riz-Borunda, J., Inst. de Biol. Molecular en Medicina, CUCS, Universidad de Guadalajara, Mexico
dc.subject.headingIndex Medicus;Acute Disease;Adult;Antirheumatic Agents/ad [Administration & Dosage];Antisense Elements (Genetics);Arthritis, Rheumatoid/dt [Drug Therapy];Arthritis, Rheumatoid/ge [Genetics];Arthritis, Rheumatoid/im [Immunology];Chronic Disease;Collagenases/ge [Genetics];Female;Gene Expression Regulation, Enzymologic/im [Immunology];Humans;Interleukin-1/ge [Genetics];Interleukin-10/ge [Genetics];Interleukin-4/ge [Genetics];Interleukin-6/ge [Genetics];Interleukins/ge [Genetics];Leukocytes, Mononuclear/en [Enzymology];Leukocytes, Mononuclear/im [Immunology];Male;Matrix Metalloproteinase 1/ge [Genetics];Matrix Metalloproteinase 13;Matrix Metalloproteinase 3/ge [Genetics];Matrix Metalloproteinases/ge [Genetics];Middle Aged;RNA, Messenger/an [Analysis];Reverse Transcriptase Polymerase Chain Reaction;Synovial Fluid/ch [Chemistry];Synovial Fluid/en [Enzymology];Synovial Fluid/im [Immunology];Tumor Necrosis Factor-alpha/ge [Genetics]
Appears in Collections:Producción científica UdeG

Files in This Item:
There are no files associated with this item.


Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.